ÂÜÀòÂÒÂ×

Hesham A. Abdullah, MD, MS, is SVP and Head of Oncology Global Clinical Development at GSK, where he oversees end-to-end strategic development and delivery of GSK’s oncology clinical-stage portfolio. Dr. Abdullah has guided multiple oncology product approvals including Iressa®, Lynparza™, Tagrisso®, Imfinzi™, Calquence®, Lumoxiti™, Zejula®, Blenrep and Jemperli. Prior to leading oncology development at GSK, Dr. Abdullah rebuilt the Late-Stage Immuno-Oncology Development and Oncology Global Regulatory Sciences functions at AstraZeneca. He started his biopharmaceutical career in Global Regulatory Affairs at Amgen, before joining Medimmune in 2011 and joining AstraZeneca in 2013. He has over 16 years of oncology and immuno-oncology drug development experience.